


# Development of the Exposure Scenario and the Role of the Industrial Hygienist



Paul Harper  
ENVIRON International Corporation  
PCIH 2009  
Vancouver, British Columbia  
October 6, 2009



# Our Discussion Points

- The REACH process
- The exposure scenario process
- Importance of the DNEL
- Derivation of the DNEL
- Comparison of DNELs and traditional occupational exposure thresholds
- Implications for the practicing industrial hygienist



## With thanks and acknowledgement to

- Denese Deeds, CIH, Industrial Health & Safety Consultants Inc.
- Kathy Thompson, CIH, 3M Company
- Linda Dell, MS, ENVIRON International
- Sue Bullock, ENVIRON International
- Fred Boelter, ENVIRON International
- Robert Skoglund, Ph.D., DABT, CIH, 3M Company
- Robert Roy, Ph.D., DABT, 3M Company
- Charles J. Alfonso, MPH, CIH, 3M Company
- Abrar Ansari


# REACH Overview


- Regulation on Registration, Evaluation and Authorisation and Restriction of Chemicals
- Passed December 18 2006, entered into force June 1, 2007
- Phased implementation over 10 years
- Estimated cost of 5 billion euro over 11 years
- References: <http://ec.europa.eu>,  
<http://echa.europa.eu>

# REACH Registration


- Phase-in for required registrations of chemicals depending on tonnages produced or imported
- Pre-registration required for all substances manufactured or imported in quantities greater than 1 tonne/year
- Pre-registration ended November 31, 2008
- Over 130,000 substances pre-registered by over 300,000 entities
- Registration for substances required by December 12, 2010 for substances that are:
  - manufactured or imported in quantities over 1000 tonnes/year
  - Over 100 tonnes/year if very toxic to the aquatic environment
  - Over 1 tonne/year if carcinogenic, mutagenic or reprotoxic (CMR)


# REACH Process






# REACH Process





# REACH Process



# The REACH Exposure Assessment

- Multiple Aspects of Exposure
  - Human Health
  - Environmental Health
  - Physical Hazards
- Through the life cycle of the substance
  - Manufacturing
  - Distribution
  - Use
  - Disposition

## ***Collectively, the Exposure Scenario***

***Today we will talk about the  
Human Health aspects of the  
Exposure Assessment***

## Exposure Scenario

- Means the set of conditions, including operational conditions and risk management measures, that describe how the substance is manufactured or used during its life-cycle and how the manufacturer or importer controls, or recommends downstream users to control, exposures of humans and the environment.
- These exposure scenarios may cover one specific process or use or several processes or uses as appropriate

(EC No 1907/2006)

## *Exposure Scenarios*



**Is Assessed  
Exposure  
Below the DNEL  
And PNEC?**

*Risk  
Management  
Measures*

*Risk  
Assessment*



**Conditions of Use**



# Exposure Assessment Overview

- Generate Exposure Scenario(s) for each life cycle stage
  - Occupational: manufacturing, formulation, professional use
  - Consumer, service life of articles, and waste
- Estimate exposure
  - based on operational conditions and risk management measures described in ES
  - Models proscribed within REACH
  - Tier 1 Models – “Reasonable Worst Case”
  - Tier 2 Models – Specific Exposure Scenario
- Characterize risk for Exposure Scenario
  - Demonstrate control of risks, safe conditions, i.e., exposure levels below DNEL or PNEC



# Sources of Data and Information

- REACH Dossier Preparation
  - Existing information
  - Information from within the Consortium
  - New data
- Substance Information Exchange Forum
  - Information from third parties
- Integrated Testing Methods
  - Weight of Evidence, QSAR, read-across




## Core principles for exposure estimation

- Based on sound scientific methodologies
- Describe the exposure of defined activities
- Actual exposure measurements preferred
- Collect all necessary information
- Account for RMMs in place
- External exposure

 REACH Exposure Assessment Process

**Exposure Scenarios**



## What is the Derived No-Effect Level (DNEL)?

- The DNEL is the level of exposure above which humans should not be exposed
  - DNEL's intended use is in REACH risk characterization
  - Established for specific substances based on population, route of entry and duration of exposure
  - Derived for chemicals having a “threshold” mode of action
  - Potential for many different DNELs because of different combinations and exposures

## Derived from typical Routes of Exposure

- Look at both Acute and Long Term Oral, Inhalation and Dermal Exposures
- Look at both Worker and General Population exposures
- DNEs may have to be established for systemic effects, local effects, or both
- Expressed as external values such as
  - mg/person-day (dermal)
  - mg/kg-day (oral)
  - mg/cm<sup>2</sup> body area-day (dermal); and
  - mg/m<sup>3</sup> (inhalation)



$$\text{DNEL} = \frac{\text{[modified] Dose Descriptor}}{\text{Total AF}}$$

$$\text{DNEL}_{\text{(Worker-Inhalation-Long-Term)}} = \text{mg/m}^3$$

# 4 Steps to DNEL Derivation

- Gather typical dose descriptors from all available studies on the different human health endpoints
  - NOAEL; LOAEL; BMD; BMDL<sub>10</sub>
  - LD<sub>50</sub>; LC<sub>50</sub>; T25 (for carcinogenic response)
  - Odds Ratio (OR); and Relative Risk (RR) [epidemiological descriptors]
- Decide on the substance's Mode of Action
  - Threshold MOA:
    - DNEL will have to be derived for that endpoint(s) based on the most relevant dose descriptor(s) for Non-carcinogens
  - Non-Threshold MOA:
    - Carcinogens
    - No DNEL will be derived
    - Derived Minimal Exposure Level (DMEL) will be calculated

# 4 Steps to DNEL Derivation

- Modify the relevant dose descriptors for each endpoint to the correct starting point
  - Route-to-route extrapolation of toxicity data
    - Oral → Dermal
    - Oral → Inhalation
    - Inhalation → Oral
  - Account for any differences between exposure conditions in experimental animal studies and that of the “target” human population(s)
  - Account for differences in respiratory volumes of experimental animals (rest) and humans (light activity)

*Adapted from Robert Roy, PhD, DABT, 3M Company*

# 4 Steps to DNEL Derivation

- Apply Assessment Factors (AFs) to the “modified” dose descriptor to get endpoint-specific DNEL
  - AFs used to account for the uncertainties in the extrapolation procedure and the available data set
    - AFs are numerical values (defaults provided)
  - AF categories:
    - Interspecies differences (allometric scaling for metabolic rate, etc.)
    - Intraspecies differences (to “cover” all sub-populations such as kids, elderly, etc.)
    - Differences in duration of exposure (sub-acute → subchronic → chronic)
    - Dose-response issues (to get to the NOAEL)
    - Quality of the entire database

*Adapted from Robert Roy, PhD, DABT, 3M Company*



*AFs for  
DNELs are  
Proscribed by  
Guidance  
Not  
Determined by  
Scientific  
Consideration*

**Table R.8.6: Default assessment factors**

Assessment factor – accounting for differences in:		Default value systemic effects	Default value local effects
Interspecies	- correction for differences in metabolic rate per body weight	AS <sup>a, b</sup>	–
	- remaining differences	2.5	1 <sup>f</sup> 2.5 <sup>g</sup>
Intraspecies	- worker	5	5
	- general population	10 <sup>c</sup>	10 <sup>c</sup>
Exposure duration	- subacute to sub-chronic	3	3 <sup>h</sup>
	- sub-chronic to chronic	2	2 <sup>h</sup>
	- subacute to chronic	6	6 <sup>h</sup>
Dose-response	- issues related to reliability of the dose-response, incl. LOAEL/NAEL extrapolation and severity of effect	1 <sup>d</sup>	1 <sup>d</sup>
Quality of whole database	- issues related to completeness and consistency of the available data	1 <sup>d</sup>	1 <sup>d</sup>
	- issues related to reliability of the alternative data	1 <sup>e</sup>	1 <sup>e</sup>

<sup>a</sup> AS = factor for allometric scaling (see Table R.8-3)

# DNEL Derivation - Example

## DNEL for Worker-Inhalation-Long-term-Systemic effects

- Step 1: NOAEL as Dose Descriptor
  - Rat 90-day inhalation NOAEL = 350 mg/m<sup>3</sup> @ 6 hours/day (liver toxicity)
- Step 2: Non-carcinogenic Mode of Action
- Step 3: Modification of Dose Descriptor
  - 350 mg/m<sup>3</sup> x 6 hr /8 hr x 6.7 m<sup>3</sup>/10 m<sup>3</sup> = 175 mg/m<sup>3</sup>
- Step 4: Apply AFs
  - 2.5 (interspecies) [no allometric scaling needed for inhalation to inhalation]; 5 (worker; intraspecies); 2 (subchronic to chronic)
- DNEL = 175 mg/m<sup>3</sup> ÷ (2.5)(5)(2) = 7 mg/m<sup>3</sup>



## Use of the DNEL: Comparison of the Modeled Occupational Exposure

*If modeled occupational exposure = 4 mg/m<sup>3</sup>*

- $\text{RCR} = 4 \text{ mg/m}^3 \div 7 \text{ mg/m}^3 = 0.6 < 1$ 
  - “risk adequately controlled”


*If modeled occupational exposure = 13 mg/m<sup>3</sup>*

- $\text{RCR} = 13 \text{ mg/m}^3 \div 7 \text{ mg/m}^3 = 1.8 > 1$ 
  - “risk is NOT controlled”

If risk is NOT controlled → apply Risk Mitigation Measures

## Derived DNEL Issues

- Derived DNEL
  - DNEL will almost always have to be derived for the Worker Long Term Inhalation scenario (Systemic Effects)
  - Per REACH – “Repeated Worker Inhalation for a Day or More”
- AFs are conservative in nature and proscribed
- Resulting DNELs are generally anticipated to be more conservative than other OELs



## A Potential Conundrum – DNELs and other Standards

- Health-based OELs
- Indicative Occupational Exposure Values (IOELs, or IOELVs)
  - Exist for about 100 substances
- National Exposure Levels
  - Exist for about 600 substances
- Non-Regulatory Exposure Thresholds

## Health-Based OELs

- Health-based OELs are prepared by a scientific committee
- The scientific community determines “overall” Safety Factor
- Consensus decision, extensive peer-review and professional comment and participation before final OEL set
- Health-based OELs have stood the “test of time”

## EU IOELs

- Directives 91/322/EEC, 2000/39/EC, and 2006/15/EC
- Health-based, non-binding values
- Derived from the most recent scientific data available taking into account the availability of measurement techniques
- Set threshold levels of exposure below which no detrimental effects are expected for a given substance
- Just over 100 IOELs established
  - [http://ec.europa.eu/employment\\_social/health\\_safety/docs/ioelvs\\_en.pdf](http://ec.europa.eu/employment_social/health_safety/docs/ioelvs_en.pdf)

## EU National OELs

- National OELs for 600+ substances
- Member states must take IOELs into account when they create their National OELs
  - Countries have adopted them as their National OELs
  - National OEL (from IOEL) may be higher or lower

# Determining the DNEL under REACH

- May use the IOEL where one exists (with certain conditions) (Appendix R.8-13)
- May use a National OEL in lieu of developing a DNEL **IF** an evaluation of the scientific background for setting the national OEL is made (no further guidance given)
- If no IOEL or National OEL exist, can consider other OELs
  - ACGIH TLV®
  - AIHA WEEL
  - German MAK
  - DECOS
  - Company OEL
- **Can use the information and data above but can't use the OEL values directly – Must Derive DNEL as proscribed**

## Issues for Consideration

- For REACH purposes...How do you derive the DNEL?
- What happens when different DNELs are derived by different registrants for the same substance?
- What happens when a non-Member State OEL, Member State OEL and DNEL for a substance are different?
- What impact does an EU DNEL have on exposure thresholds in other countries?
- How does the Industrial Hygienist utilize the information?

## DNELEs versus existing OELs

- DNELEs will be driven primarily from worker long term inhalation exposures
- OELs, largely, are derived for a larger body of evidence
- DNELEs are anticipated to be more conservative, i.e. lower, than corresponding OELs
- May in fact be significantly lower



# Examples

Chemical	Health-Based OEL	EU IOEL	National OEL	DNEL	Company OEL
Chemical S	1 ppm	---	5 ppm	~ 0.1 ppm	---
A Glycol Ether	5 ppm	---	2 ppm	~ 1.6 ppm	---
Chemical C	100 ppm	200 ppm		~ 50 ppm	---
Chemical MA	200 ppm	---	200 ppm	~ 10 ppm	---
Chemical PP	50 ppm	---	20-25 ppm	~ 5 ppm	---
Chemical M	200 ppm	200 ppm	200 ppm	~ 55 ppm	

*Adapted from Robert Roy, PhD, DABT, 3M Company*



## In Practice

- REACH DNELs are used to conduct a Safety Assessment and determine Conditions of Use for substances in certain Exposure Scenarios
  - May be existing conditions of use or may impose Risk Mitigation Measures to bring exposure below DNEL
- REACH DNELs do not displace Regulatory OELs
  - Facilities must maintain exposures below Regulatory OELs



## In Practice

- DNELs may impact substance (and product) distribution and use in the EU
- These conditions of use may spill over to non-EU countries and states
- Users are still required to comply with Regulatory OELs
- Industrial Hygienists may be faced with contradictory exposure restrictions to apply in their specific situations
- There is a potential in the future for DNELs to supplant OELs, either in practice or force, but that remains to be seen



## Summary

- Industrial Hygienists face some significant challenges in reconciling OELs in their regions with DNELs and conditions of use potentially proscribed in Safety Data Sheets
- Industrial Hygienists play and need to understand their significant roles in REACH
  - Development of OES(s)
  - Estimation of exposure
  - Identification of effective RMM/OC
  - Iteration of the OES(s)